Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted EBT Margin of 15.25% for Q1 2026, up 50.43% on a QoQ basis from 10.14% in Q4 2025, and up 396.0% year-over-year from 3.08% in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's EBT Margin history runs 6 years deep, the most recent figure standing at 15.25% for Q1 2026.
- Quarterly EBT Margin rose 396.0% year-over-year to 15.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.69% (up 908.0% YoY) and the FY2025 annual result came in at 12.71%, up 1452.0% from the prior year.
- EBT Margin was 15.25% for Q1 2026 at Kiniksa Pharmaceuticals International, up from 10.14% in the prior quarter.
- Across five years, EBT Margin topped out at 59.51% in Q4 2022 and bottomed at 86.37% in Q4 2023.
- A 5-year average of 6.1% and a median of 2.12% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 45491 bps — and 2023, when it plunged 14588 bps.
- Kiniksa Pharmaceuticals International's EBT Margin stood at 59.51% in 2022, then plunged by 245 bps to 86.37% in 2023, then jumped by 111 bps to 9.38% in 2024, then gained by 8 bps to 10.14% in 2025, then soared by 50 bps to 15.25% in 2026.
- Business Quant data shows KNSA's EBT Margin at 15.25% in Q1 2026, 10.14% in Q4 2025, and 15.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 15.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.25% |
| Dec 31, 2025 | 10.14% |
| Sep 30, 2025 | 15.02% |
| Jun 30, 2025 | 14.59% |
| Mar 31, 2025 | 11.30% |
| Dec 31, 2024 | 9.38% |
| Sep 30, 2024 | -6.42% |
| Jun 30, 2024 | 2.12% |
| Mar 31, 2024 | -17.88% |
| Dec 31, 2023 | -86.37% |
| Sep 30, 2023 | -12.68% |
| Jun 30, 2023 | -1.73% |
| Mar 31, 2023 | -19.37% |
| Dec 31, 2022 | 59.51% |
| Sep 30, 2022 | 47.14% |
| Jun 30, 2022 | -71.43% |
| Mar 31, 2022 | -72.34% |
| Dec 31, 2021 | -233.66% |
| Sep 30, 2021 | -253.51% |
| Jun 30, 2021 | -526.34% |